trending Market Intelligence /marketintelligence/en/news-insights/trending/MwUriSMd4e9uO4afiHuYRw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

MorphoSys sells right to cancer drug for $750M upfront

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


MorphoSys sells right to cancer drug for $750M upfront

Germany's MorphoSys AG sold the rights to its cancer therapy tafasitamab to Incyte Corp. for an upfront payment of $750 million.

Incyte will have the exclusive commercialization rights to the medicine around the globe, except in the U.S., where the rights will be held by both pharmaceutical companies. Wilmington, Del.-based Incyte will make a separate $150 million investment in MorphoSys under the agreement, and said it will pay up to a further $1.1 billion if the medicine meets certain developmental, regulatory and commercial milestones.

MorphoSys will lead the commercialization strategy and book all revenues from the sales of tafasitamab in the U.S., but share half of the profits — or losses — from the country with Incyte. Tafasitamab is under review in the U.S. as a treatment for blood cancer, with a U.S. Food and Drug Administration decision expected later this year.

Outside the U.S., Incyte will book all revenues from the sales of tafasitamab and pay MorphoSys royalties on such sales. The companies plan to file for EU approval of the drug in mid-2020, and Incyte has plans to pursue development in additional territories include China and Japan.

Tafasitamab is being touted as a treatment for diffuse large B cell lymphoma — a type of blood cancer — in patients who stop responding to other therapies or whose cancer returned. Both parties will also study the medicine in other cancer types, such as follicular lymphoma, marginal zone lymphoma and chronic lymphocytic leukemia.

The agreement between MorphoSys and Incyte, including the equity investment, is subject to clearance by U.S., German and Austrian authorities and will become effective as soon as these conditions have been met.